Chattanooga Medical Research LLC. | Chattanooga, TN
Status and phase
Conditions
Treatments
About
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested.
Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity.
The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy.
Parts A, B, and C of the study are looking at several other research questions, including:
Full description
Part A Healthy Volunteers
Part B and Part C (starts after treatment for Part A has completed) Participants with Obesity
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria
Part A
Male or female participants age ≥18 to ≤55 years of age at the time of screening
BMI ≥18 and ≤32 kg/m2, at the screening visit
Part B and Part C
Male or female participants ≥18 to ≤80 years of age at the time of screening
BMI ≥30 kg/m2, at the screening visit
History of 1 or more self-reported unsuccessful dietary attempts to lose weight
Key Exclusion Criteria
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Primary purpose
Allocation
Interventional model
Masking
999 participants in 13 patient groups, including a placebo group
Loading...
Central trial contact
Clinical Trials Administrator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal